Neuroscience Biotech LB Files for $228M IPO to Support Phase III Plans
If LB is successful, the debut would mark the first IPO in months for the sector, as the biotech industry continues to endure a nuclear winter.
Neuroscience Biotech LB Files for $228M IPO to Support Phase III Plans Read More »
